Primary literature evidence
Search paper-level observations with their value, target, assay, evidence sentence, source location, and stable record links. Evidence without a safely standardized sequence remains visible without being misrepresented as a canonical peptide.
Evidence records
the range of antimicrobial activity of the hybrid peptide matched, or came within one dilution, of that of the template AMP (protonecin and temporin A, 3.1–25 μmol L−1).
The MIC values of protonectin, PV and VP against P. aeruginosa were 128 μmol L−1 (Fig. 3a and Tables S1 and S2).
Anoplin and protonectin were not active against Bacillus subtilis at the range of concentrations tested.
Within 4 h of incubation with MCF-7, protonectin and temporin A reduced the counts of viable MCF-7 cells (LD50: 25 μmol L−1 and 50 μmol L−1, respectively).
After 24 h of incubation, protonectin and temporin A exhibited the same LD50 (LD50: 25 μmol L−1 and 50 μmol L−1, respectively).
The markedly improved hemolytic profile of VP (hemolytic at 100 μmol L−1) compared to the parent peptide protonectin (hemolytic at 12.5 μmol L−1) or to PV (hemolytic at 25 μmol L−1)
After 24 h of incubation, we did not observe peptide-meditated cytotoxicity towards MCF-10A cells (Fig. 3e).
Names such as P1, PEP1, or peptide 1 are paper-local labels. Search results group them by publication and never assume cross-paper molecular identity without sequence or explicit structural evidence.
